Last reviewed · How we verify
IRON SUCROSE
IRON SUCROSE is a Parenteral Iron Replacement [EPC] drug. It is currently FDA-approved (first approved 2000).
Iron sucrose is a small molecule supplement used to treat conditions such as iron deficiency, anemia, and anemia of chronic kidney disease. It is studied in clinical trials for the treatment of kidney disease and kidney failure.
At a glance
| Generic name | IRON SUCROSE |
|---|---|
| Drug class | Parenteral Iron Replacement [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
Common side effects
- Headache
- Respiratory tract viral infection
- Peritonitis
- Vomiting
- Pyrexia
- Dizziness
- Cough
- Nausea
- Arteriovenous fistula thrombosis
- Hypotension
- Hypertension
- Cardiac failure congestive
Serious adverse events
- Anaphylactic-type reactions
- Angioedema
- Convulsions
- Shock
- Acute myocardial ischemia
- Myocardial infarction
- Bronchospasm
- Dyspnea
- Loss-of-consciousness
- Collapse
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
- Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (NA)
- Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery (EARLY_PHASE1)
- Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin (PHASE2)
- Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy (PHASE3)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IRON SUCROSE CI brief — competitive landscape report
- IRON SUCROSE updates RSS · CI watch RSS
Frequently asked questions about IRON SUCROSE
What is IRON SUCROSE?
What drug class is IRON SUCROSE in?
When was IRON SUCROSE approved?
What development phase is IRON SUCROSE in?
What are the side effects of IRON SUCROSE?
Related
- Drug class: All Parenteral Iron Replacement [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing